For the Quarter Ending September 2025
North America
• In the United States, Amitriptyline Hydrochloride Price Index rose in Q3 2025, driven by elevated production costs.
• Amitriptyline Hydrochloride production costs increased as the Producer Price Index rose 2.6% in August 2025.
• Demand for Amitriptyline Hydrochloride showed an upward trajectory in the US pharmaceutical market during Q3 2025.
• Natural gas feedstock costs, a key production driver, spiked in Q3 2025, increasing manufacturing expenses.
• Manufacturing inventories for chemical producers, including raw materials, shrank significantly in Q3 2025.
• The Consumer Price Index increased 3.0% in September 2025, impacting patient affordability for Amitriptyline Hydrochloride.
• US industrial production saw a slight 0.1% increase in September 2025, indicating subdued manufacturing activity.
• Retail sales, excluding auto and gas, rose 5.42% in September 2025, supporting overall healthcare spending.
• A stable unemployment rate of 4.3% in September 2025 supported healthcare access, despite declining consumer confidence to 94.2.
Why did the price of Amitriptyline Hydrochloride change in September 2025 in North America?
• Amitriptyline Hydrochloride production costs rose due to a 2.6% PPI increase in August 2025.
• Natural gas feedstock prices spiked in Q3 2025, elevating manufacturing expenses significantly.
• Manufacturing inventories shrank, and raw material levels turned negative in Q3 2025.
APAC
• In China, the Amitriptyline Hydrochloride Price Index fell quarter-over-quarter in Q3 2025, driven by weakening producer prices and chemical overcapacity.
• Amitriptyline Hydrochloride production costs decreased in Q3 2025, as China's Producer Price Index (PPI) fell 2.3% year-on-year.
• Demand outlook for Amitriptyline Hydrochloride is stable, supported by robust pharmaceutical market growth in Q3 2025.
• China's industrial production expanded 6.5% year-on-year in September 2025, supporting stable supply chains.
• Overall chemical feedstock costs eased in China during Q3 2025, contributing to lower production expenses.
• China's Manufacturing Index was contracting in September 2025, signaling a broader slowdown.
• Pharmaceutical and API exports from China strengthened in Q3 2025, indicating robust international demand.
• The broader chemical industry in China experienced significant overcapacity in Q3 2025, influencing market dynamics.
Why did the price of Amitriptyline Hydrochloride change in September 2025 in APAC?
• Producer Price Index (PPI) fell 2.3% year-on-year in September 2025, reducing manufacturing costs.
• China's broader chemical industry faced significant overcapacity in Q3 2025, increasing supply pressure.
• Deflationary pressures, with CPI falling 0.3% year-on-year in September 2025, impacted overall pricing.
Europe
• In Germany, the Amitriptyline Hydrochloride Price Index remained stable quarter-over-quarter in Q3 2025, influenced by mixed cost and demand signals.
• Amitriptyline Hydrochloride production costs experienced downward pressure in September 2025 due to a 1.7% decline in PPI year-over-year.
• Conversely, rising CPI by 2.4% year-over-year in September 2025 increased operational costs for manufacturers.
• Demand for Amitriptyline Hydrochloride remained consistent in Q3 2025, supported by Germany's aging population and chronic disease prevalence.
• The Manufacturing Index contracted in September 2025, indicating potential supply chain challenges for chemical precursors.
• European natural gas prices showed a steady downward trend in Q3 2025, easing energy-related production expenses.
• Benzene prices stabilized in early Q3 2025, while naphtha feedstock costs influenced o-xylene production trends.
• A low unemployment rate of 3.9% in September 2025 supported stable healthcare spending and patient access.
• The Amitriptyline Hydrochloride price forecast suggests continued stability, balancing cost pressures with inelastic pharmaceutical demand.
Why did the price of Amitriptyline Hydrochloride change in September 2025 in Europe?
• Decreasing PPI by 1.7% in September 2025 reduced raw material and energy input costs for producers.
• Stable demand for essential pharmaceuticals, driven by an aging population in Q3 2025, provided price support.
• Rising CPI by 2.4% in September 2025 increased general operational expenses for manufacturing.
For the Quarter Ending December 2022
North America
The prices of Amitriptyline Hydrochloride in the United States mimic similar market sentiments as that of India. Until November, the prices inclined moderately on the back of consistent end-user demand from the domestic market balanced with the overall supplies among the market participants.
However, as the year ends, the prices for Amitriptyline Hydrochloride dropped gradually in December 2022, which resulted in the stockpiling of inventories among the market players, propelling the m to reduce their prices in order to destock their stockpiles and maintain their profit. Additionally, a decrease in shipping costs, slower consumer demand, and a temporary shutdown of the domestic market kept the price trend of Amitriptyline Hydrochloride on the weaker side.
APAC
Amitriptyline Hydrochloride prices witnessed a declining trend throughout the fourth quarter of 2022 in the Asia Pacific region. Compared to the previous quarter, the prices inclined stably until November and dropped considerably during the last month of the fourth quarter. A slight increase in demand and sufficient inventories among the market players kept the prices of Amitriptyline Hydrochloride on the upper side. Rising energy prices additionally impacted the market sentiments of all the sectors, including Pharmaceutical as operational charges and the cost of upstream material also inclined until the mid of the final quarter of 2022. Following December, the prices for Amitriptyline Hydrochloride dropped considerably owing to bearish demand balanced with the overall stored inventories. Overall, the price of Amitriptyline Hydrochloride noted at the end of the fourth quarter was assembled at USD 33810.77/MT Ex Ahmedabad in India.
Europe
In the fourth quarter of 2022, the European market for Amitriptyline Hydrochloride also followed a similar pattern to that of Asia Pacific. The market trend initially started on a healthy note until November in Germany, primarily due to increased demand from the end-user pharmaceutical industry. Inquiries from the downstream sector for Amitriptyline Hydrochloride prices began to decrease significantly after November, with abundant supplies with the market participants. In addition to that, traders also cut back their placed orders in order to prevent further stockpiling.
For the Quarter Ending September 2022
North America
The Amitriptyline Hydrochloride market showcased declined pricing sentiments during the third quarter of 2022 in the North American region, backed by reduced demand from the downstream pharmaceutical industries amidst weaker customer inquiries and overflowed inventories in the market. Furthermore, the fluctuation in energy values and freight charges also led to the instability in the price of Amitriptyline Hydrochloride during this quarter. Also, the domestic market participants had enough stocks to meet the overall requirements during the third quarter in the United States. By the termination of the third quarter, the prices of Amitriptyline Hydrochloride ended with a decrement trend only.
APAC
In the APAC region, the prices of Amitriptyline Hydrochloride witnessed a mixed market sentiment throughout the third quarter of 2022. At the onset of h1, the prices declined considerably owing to waken demand and sufficient inquiries with the domestic market participants. Further, towards the end of h1 and the start of h2, the prices went on the upper side owing to a slight incremented demand. Additionally, supply disruption and Healthy demand in the market supported the price tendency of Amitriptyline Hydrochloride in the overall market. Followed by this again towards the end of q3, the prices dropped significantly by -1.60% and got settled at USD 30109/MT Ex Ahmedabad in India.
Europe
The market of Amitriptyline Hydrochloride mimics a similar price trajectory as in North America during the third quarter of 2022 in the European Region. This trend was supported by lessening demand and Supply, and demand remained steady as the market participants were left with enough stock to cater to the overall demand side. Additionally, fluctuations in trade frequency during the whole quarter also affected the market value of Amitriptyline Hydrochloride. Also, the slow offtake from downstream pharmaceuticals was one of the factors behind this weak price trend of Amitriptyline Hydrochloride in Germany. Overall weaker demand, stockpiled inventories, and Russian- the Ukraine war were some of the factors that kept the prices on the lower side
